Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile

JAMA

Volumn 281, Issue 16, 1999, Pages 1520-1527

  Tappero, Jordan W ^a   Lagos, Rosanna ^b,c   Ballesteros, Aurora Maldonado ^d   Plikaytis, Brian ^a   Williams, Derrick ^a   Dykes, Janet ^a   Gheesling, Linda L ^a   Carlone, George M ^a   Høiby, E Arne ^g   Holst, Johan ^g   Nøkleby, Hanne ^g   Rosenqvist, Einar ^g   Sierra, Gustavo ^h   Campa, Concepción ^h   Sotolongo, Franklin ^h   Vega, Jeanette ^e   Garcia, Julio ^d   Herrera, Patricio ^f   Poolman, Jan T ^i,j   Perkins, Bradley A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HOSPITAL ROBERTO DEL RÍO   (Chile)

^c Centro para Vacunas en Desarrollo Chile   (Chile)

^d INSTITUTO DE SALUD PÚBLICA DE CHILE   (Chile)

^e Pan American Health Organization   (Chile)

^f UNIVERSITY OF CHILE   (Chile)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h FINLAY INSTITUTE   (Cuba)

ⁱ NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^j GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHEMA; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NUCLEOTIDE SEQUENCE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPING; SERUM BACTERICIDAL ACTIVITY; VACCINATION; VOMITING;

EID: 0033611936     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.16.1520     Document Type: Article

References (55)

1. Wenger JD, Perkins BA. Patterns in emergence of epidemic meningococcal disease. In: Scheld WM, Armstrong SD, Hughes JM, eds. Emerging Infectious Diseases I. Washington, DC: ASM Press; 1998:125-136.
2. Murray JCL. Global health statistics. In: Murray JCL, Lopez AD, eds. Global Burden of Disease and Injury Series. Vol 2. Boston, Mass: Harvard University Press; 1996:292-297.
3. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis. 1998;177:497-500.
4. Centers for Disease Control and Prevention. Serogroup B meningococcal disease - Oregon, 1994. MMWR Morb Mortal Wkly Rep. 1995;44:121-124.
5. Fischer M, Perkins BA. Neisseria meningitidis serogroup B. Semin Pediatr Infect Dis. 1997;8:50-56.
6. Centers for Disease Control and Prevention. Out-breaks of serogroup B meningococcal disease. MMWR Morb Mortal Wkly Rep. 1998;47:833-837.
7. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338: 1093-1096.
8. Sierra GVG, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14:195-207.
9. de Moraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-1078.
10. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 1995;13:821-829.
11. Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide vaccine. Lancet. 1985;2:114-118.
12. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease. MMWR Morb Mortal Wkly Rep. 1997;46:1-21.
13. Rosenstein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 1998;279:435-439.
14. Wyle FA, Artenstein MS, Brandt BL, et al. Immunologic response in man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972;126:514-521.
15. Mandrell RE, Zollinger WD. Measurement of antibodies to serogroup B meningococcal polysaccharide. J Immunol. 1982;129:2172-2178.
16. Finne JM, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Lancet. 1983;2:355-357.
17. Diaz Romero J, Outschoorn IM. Current status of meningococcal group B vaccine candidates. Clin Microbiol Rev. 1994;7:559-575.
18. Frasch CE. Meningococcal vaccines. In: Cartwright KAV, ed. Meningococcal Disease. New York, NY: John Wiley & Sons Inc; 1995:245-283.
19. Zollinger WD. New and improved vaccines against meningococcal disease. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines. New York, NY: Marcel Dekker Inc; 1997:469-488.
20. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I: role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
21. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, II. J Exp Med. 1969;129:1327-1348.
22. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus, IV. J Exp Med. 1969;129:1367-1384.
23. Høiby EA, Rosenqvist E, Frøholm LO, et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief summary. Natl Inst Public Health Ann. 1991;14:147-156.
24. Rosenqvist E, Høiby EA, Wedege E, Kusecek B, Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis. 1993;167:1065-1073.
25. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994; 62:4419-4424.
26. Aase A, Bjune G, Høiby EA, Rosenqvist E. Pedersen AK, Michaelsen TE. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun. 1995;63:3531-3536.
27. Rosenqvist E, Høiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995; 63:4642-4652.
28. Peeters CCAM, Rümke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent porA containing meningococcal outer membrane vesicle vaccine. Vaccine. 1996;14:1009-1015.
29. Van der Voort ER, Van der Ley P, Van der Biezen J, et al. Specificity of human bactericidal antibodies against porA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun. 1996;64:2745-2751.
30. Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998;177:683-691.
31. Hitchcock PJ. Unified nomenclature for pathogenic Neisseria species. Clin Microbiol Rev. 1989;2 (suppl):S64-S65.
32. Jones GR, Christodoulides M, Brooks JL, Miller AR, Cartwright KA, Heckels JE. Dynamics of carriage of Neisseria meningitidis in a group of military recruits. J Infect Dis. 1998;178:451-459.
33. Idanpaan-Heikkila I, Høiby EA, Chattopadhyay P, Airaksinen U, Michaelsen TM, Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol. 1995;43:335-343.
34. Tappero J, Gassibe P, Castillo L, Reeves M, Perkins B. Epidemic of clonal serogroup B meningococcal disease in Chile. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 4-7, 1994; Orlando, Fla. Abstract J13.
35. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991;14:67-80.
36. Wedege E, Høiby EA, Rosenqvist E, Frøholm LO. Serotyping and subtyping of Neisseria meningitidis isolated by co-agglutination, dot-blotting and ELISA. J Med Microbiol. 1990;31:195-201.
37. Caugant DA, Frøholm LO, Bøvre K, et al. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci U S A. 1986;83: 4927-4931.
38. Reeves MW, Perkins BA, Diermeyer M, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis. 1995;1:53-54.
39. Cruz C, Pavez G, Aguilar E, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol Infect. 1990;105:119-126.
40. Dean AG, Dean JA, Coulombier D, et al. Epi Info, Version 6: A Word Processing, Database, and Statistics Program for Epidemiology on IBM-Compatible Microcomputers. Atlanta, Ga: Centers for Disease Control and Prevention; 1994.
41. SAS/STAT User's Guide, Version 6. Cary, NC: SAS Institute Inc; 1990.
42. Estabrook NM, Baker CJ, Griffiss JM. The immune response of children to meningococcal lipooligosaccharides during disseminated disease is directed primarily against 2 monoclonal-antibody defined epitopes. J Infect Dis. 1993;167:966-970.
43. Sacchi CT, Pessoa LL, Ramos SR, et al. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased prevalence of a single clone of the ET-5 complex. J Clin Microbiol. 1992;30:1734-1738.
44. Frasch CE, Zollinger WD, Poolman JT. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis. 1985;7:504-510.
45. McGuinness BT, Lambden PR, Heckels JE. Class 1 outer membrane protein of Neisseria meningitidis. Mol Microbiol. 1993;7:505-514.
46. Wedege E, Dalseg R, Caugant DA, Poolman JT, Frøholm LO. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J Med Microbiol. 1993;38:23-28.
47. Suker J, Feavers IM, Achtman M, Morelli G, Wang JF, Maiden MCJ. The porA gene in serogroup A meningococci. Mol Microbiol. 1994;12:253-265.
48. Brooks JL, Fallon RJ, Heckels JE. Class 1 outer membrane protein in Neisseria meningitidis isolated from patients with meningococcal infection and close household contacts. FEMS Microbiol Lett. 1995;128:145-150.
49. Sacchi CT, Lemos APS, Brandt ME, et al. Proposed standardization of Neisseria meningitidis porA variable-region typing nomenclature. Clin Diagn Lab Immunol. 1998;5:845-855.
50. McGuinness BT, Clarice IN, Lambden PR, et al. Point mutation in meningococcal porA gene associated with increased endemic disease. Lancet. 1991; 337:514-517.
51. Centers for Disease Control and Prevention. Laboratory-based surveillance for meningococcal disease in selected areas - United States, 1989-1991. MMWR Morb Mortal Wkly Rep. 1993;42(SS-2):21-30.
52. Kaczmarski EB. Meningococcal disease in England and Wales: 1995. Commun Dis Rep CDR Rev. 1997;7:R55-R59.
53. Schuchat A, Robinson KA, Wenger JD, et al, and the Active Surveillance Team. Bacterial meningitis in the United States in 1995. N Engl J Med. 1997;337: 970-976.
54. Borrow R, Clark S, Sadler F, et al. Effect of sequence variation in the meningococcal porA OMP on the immunogenicity of a recombinant porA meningococcal vaccine in UK infants. In: Nassif X, Quentin-Millet M-J, Taha M-K, eds. Eleventh International Pathogenic Neisseria Conference. Paris, France: Editions Médicales et Scientifiques; 1998:178.
55. Cartwright K, Morris R, Rümke H, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (porA) outer membrane proteins. Vaccine. In press.